Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies

Genes Chromosomes and Cancer

Volumn 46, Issue 9, 2007, Pages 796-804

  Schenk, Tino ^a   Stengel, Sven ^a,c   Goellner, Stefanie ^a,d   Steinbach, Daniel ^b,e   Saluz, Hans Peter ^a  

^a HANS KNÖLL INSTITUTE   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c ROBERT KOCH INSTITUTE   (Germany)

^d FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

^e UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MELANOMA ANTIGEN; PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; CANCER DIAGNOSIS; CANCER GENETICS; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA FLANKING REGION; DNA METHYLATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MINIMAL RESIDUAL DISEASE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY MECHANISM; SEQUENCE ANALYSIS; TRANSCRIPTION REGULATION;

5' FLANKING REGION; ANTIGENS, NEOPLASM; BONE MARROW; CELL LINE, TUMOR; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; PROMOTER REGIONS (GENETICS); TRANSCRIPTION, GENETIC;

EID: 34547094548     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20465     Document Type: Article

References (30)

1. Aerts JL, Gonzales MI, Topalian SL. 2004. Selection of appropriate control genes to assess expression of tumor antigens using real-time RT-PCR. Biotechniques 36:84-86.
2. Bird AP, Wolffe AP. 1999. Methylation-induced repression - Belts, braces, and chromatin. Cell 99:451-454.
3. Boon K, Edwards JB, Siu IM, Olschner D, Eberhart CG, Marra MA, Strausberg RL, Riggins GJ. 2003. Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. Oncogene 22:7687-7694.
4. Chambost H, van Baren N, Brasseur F, Olive D. 2001. MAGE-A genes are not expressed in human leukemias. Leukemia 15:1769-1771.
5. de Smet C, Lurquin C, Lethe B, Martelange V, Boon T. 1999. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 19:7327-7335.
6. de Smet C, Loriot A, Boon T 2004. Promoter-dependent mechanism leading to selective hypomethylation within the 5′ region of gene MAGE-A1 in tumor cells. Mol Cell Biol 24:4781-4790.
7. Doerfler W, Weisshaar B, Hoeveler A, Knebel D, Muller U, Dobrzanski P, Lichtenberg U, Achten S, Hermann R. 1988. Promoter inhibition by DNA methylation: A reversible signal. Gene 74:129-133.
8. Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R. 2005. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 122:835-847.
9. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL. 1992. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 89:1827-1831.
10. Goellner S, Steinbach D, Schenk T, Gruhn B, Zintl F, Ramsay E, Saluz HP. 2006. Childhood acute myelogenous leukaemia: Association between PRAME, apoptosis- and MDR-related gene expression. Eur J Cancer 42:2807-2814.
11. Greiner J, Ringhoffer M, Simikopinko O, Szmaragowska A, Huebsch S, Maurer U, Bergmann L, Schmitt M. 2000. Simultaneous expression of different immunogenic antigens in acute myeloid leukemia. Exp Hematol 28:1413-1422.
12. Griffioen M, Kessler JH, Borghi M, van Soest RA, van der Minne CE, Nouta J, van der Burg SH, Medema JP, Schrier PI, Falkenburg JH, Osanto S, Melief CJ. 2006. Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy. Clin Cancer Res 12:3130-3136.
13. Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG. 1997. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199-208.
14. Ikeda H, Matsushita M, Kawakami H. 1999. PRAME protein expressed in leukemia cells as a target molecule for immunotherapy. Rinsho Ketsueki 40:484-486.
15. Li L, Giannopoulos K, Reinhardt P, Tabarkiewicz J, Schmitt A, Greiner J, Rolinski J, Hus I, Dmoszynska A, Wiesneth M, Schmitt M. 2006. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. Int J Oncol 28:855-861.
16. Matsushita M, Ikeda H, Kizaki M, Okamoto S, Ogasawara M, Ikeda Y, Kawakami Y. 2001. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br J Haematol 112:916-926.
17. McElwaine S, Mulligan C, Groet J, Spinelli M, Rinaldi A, Denyer G, Mensah A, Cavani S, Baldo C, Dagna-Bricarelli F, Hann I, Basso G, Cotter FE, Nizetic D. 2004. Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker. Br J Haematol 125:729-742.
18. Nguyen CT, Gonzales FA, Jones PA. 2001. Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation. Nucleic Acids Res 29:4598-4606.
19. Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M. 2004. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res 10:4307-4313.
20. Paydas S, Tanriverdi K, Yavuz S, Disel U, Baslamisli F, Burgut R. 2005. PRAME mRNA levels in cases with acute leukemia: Clinical importance and future prospects. Am J Hematol 79:257-261.
21. Pfaffl MW. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45.
22. Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, Sawyers C, Shah N, Stock W, Willman CL, Friend S, Linsley PS. 2006. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 103:2794-2799.
23. Razin A. 1998. CpG methylation, chromatin structure and gene silencing-a three-way connection. EMBO J 17:4905-4908.
24. Sigalotti L, Fratta E, Coral S, Tanzarella S, Danielli R, Colizzi F, Fonsatti E, Traversari C, Altomonte M, Maio M. 2004. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2′-deoxycytidine. Cancer Res 64:9167-9171.
25. Steinbach D, Hermann J, Viehmann S, Zintl F, Gruhn B. 2002a. Clinical implications of PRAME gene expression in childhood acute mveloid leukemia. Cancer Genet Cytogenet 133:118-123.
26. Steinbach D, Viehmann S, Zintl F, Gruhn B. 2002b. PRAME gene expression in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet 138:89-91.
27. Steinbach D, Schramm A, Eggert A, Onda M, Dawczynski K, Rump A, Pastan I, Wittig S, Pfaffendorf N, Voigt A, Zintl F, Gruhn B. 2007. Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia. Clin Cancer Res 12:2434-2441.
28. Szyf M. 2001. Towards a pharmacology of DNA methylation. Trends Pharmacol Sci 22:350-354.
29. van Baren N, Chambost H, Ferrant A, Michaux L, Ikeda H, Millard I, Olive D, Boon T, Coulie PG. 1998. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol 102:1376-1379.
30. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der KK, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536.